Home/Pipeline/Vyxeos

Vyxeos

Acute Myeloid Leukemia (AML)

MarketedActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Marketed

Status

Active

Company

Jazz Pharmaceuticals

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is a global biopharmaceutical company with a mission to develop and commercialize life-changing medicines for patients with rare diseases and unmet needs. The company has achieved significant scale with a market cap of $11.32B, a portfolio of marketed products, and a robust pipeline, driven by a sharpened strategic focus on rare diseases. Its strategy combines internal R&D with disciplined business development to build a sustainable, innovative portfolio, supported by a global commercial footprint and manufacturing infrastructure.

View full company profile

Therapeutic Areas

Rare Epilepsies Oncology Sleep Disorders

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active